Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03472274
Title Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO) (DUTRENEO)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Fundacion CRIS de Investigacion para Vencer el Cancer

urethra transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

ureter transitional cell carcinoma


Cisplatin + Doxorubicin + Methotrexate + Vinblastine

Cisplatin + Gemcitabine

Cisplatin + Gemcitabine + Paclitaxel

Durvalumab + Tremelimumab

Age Groups: adult | senior
Covered Countries ESP

No variant requirements are available.